Physician profile
Brea C Lipe
NPI 1760542088
$129,344.43
in general payments reported to CMS, 2019-2025
17 companies · $47K in 2025
The $47K reported for 2025 was more than what 96% of Hematology & Oncology providers received nationally (typical 2025 total: $686).
Payments by year
General payments by program year, as reported to CMS.
General payments by year: 2019: $9,570 · 2020: $14K · 2021: $11K · 2022: $7,862 · 2023: $30K · 2024: $10K · 2025: $47K.
What the payments were for
Nature of payment as categorized by the reporting companies: meals, consulting, travel, and so on.
Compensation For Services Other Than Consulting, Including Serving As Faculty Or As A Speaker At A Venue Other Than A Continuing Education Program: $54K · Consulting Fee: $27K · Travel and Lodging: $3,738 · Food and Beverage: $2,270 · Honoraria: $750 · Education: $17.16.
View as a table
| Payment type | Amount (2023-2025) |
|---|---|
| Compensation For Services Other Than Consulting, Including Serving As Faculty Or As A Speaker At A Venue Other Than A Continuing Education Program | $53,995.00 |
| Consulting Fee | $26,572.60 |
| Travel and Lodging | $3,737.66 |
| Food and Beverage | $2,270.21 |
| Honoraria | $750.00 |
| Education | $17.16 |
Payment-type detail covers 2023-2025; earlier years are included in totals but not broken out here.
Who reported paying
General payments only, as reported to CMS. Product names cover 2023-2025.
| Company | General payments | Years | Top products |
|---|---|---|---|
| Genzyme Corporation | $50,567.31 | 2020-2025 | |
| Sanofi-Aventis U.S. LLC | $16,941.88 | 2023 | |
| Janssen Scientific Affairs, LLC | $14,417.48 | 2022-2025 | Darzalex |
| Janssen Biotech, INC. | $13,095.15 | 2020-2025 | Darzalex, Tecvayli, Talvey |
| Amgen INC. | $9,569.97 | 2019 | |
| Glaxosmithkline, LLC. | $5,618.80 | 2020-2025 | Blenrep |
| Celgene Corporation | $5,249.14 | 2020-2023 | Pomalyst |
| Karyopharm Therapeutics INC. | $4,643.66 | 2020-2024 | Xpovio |
| Takeda Pharmaceuticals U.S.A., INC. | $2,790.00 | 2021 | |
| E.R. Squibb & Sons, L.L.C. | $2,422.00 | 2024 | |
| Legend Biotech USA INC. | $2,180.85 | 2025 | Carvykti |
| Janssen Global Services, LLC | $1,365.00 | 2023-2025 | Tecvayli |
| Sobi, INC | $200.00 | 2024 | |
| Genentech, INC. | $149.78 | 2022 | |
| Janssen Research & Development, LLC | $116.25 | 2024 |
Show all 16 companies
| Company | General payments | Years | Top products |
|---|---|---|---|
| Pfizer INC. | $17.16 | 2025 |
1 company reported research payments only; those appear in the research section below.
Drugs and devices associated with these payments
CMS records which products a payment was associated with, not how the money was allocated. Association is not allocation: one payment can be associated with several products, and a product listing does not mean the payment was made because of that product. Product detail covers 2023-2025.
If you want to bring it up
Most clinicians are glad to talk about this. A respectful way in:
- "I saw Brea Lipe listed in the CMS Open Payments database. Can you tell me about your work with those companies?"
- "Is there a generic or alternative to this medication, and would it work as well for me?"
- "What made you choose this particular treatment for my situation?"
These are normal questions. A good clinician will welcome them.
Share this page
Keep an eye on this page
Get an email when the next June refresh changes this page. No account needed.
Source: CMS Open Payments, program years 2019-2025, as reported to CMS by drug and device makers (published June 30, 2026). Drug and device detail covers 2023-2025.